Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 6;130(8):581–594. doi: 10.1002/cncy.22594

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Cancer Cytopathology published by Wiley Periodicals LLC on behalf of American Cancer Society.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Representative examples of FAST‐fine‐needle aspiration (FNA) analysis. (A) Single‐cell staining with a panel of salivary gland tumor (SGT)‐relevant antibodies (pleomorphic adenoma [PA], mucoepidermoid carcinoma [MuEC], salivary duct carcinoma [SDC], adenoid cystic carcinoma [AdCC]). Antibodies were conjugated to FAST probes with one of the following fluorophores: Alexa fluor 488, Alexa fluor 555, or Alexa fluor 647. (B) FAST‐FNA analysis of SGT subtypes (PA, n = 19; MuEC, n = 3; SDC, n = 4; AdCC, n = 6; all malignant tumors n = 24) showing high expression levels of different biomarkers of each SGT subtype. Sample positivity was determined if more than 20% of tumor cells expressed the respective marker. The percentages refer to the number of patients in whom a given biomarker was positive.